The largest community of pharma leaders

Blackstone invests $2 billion in Alnylam, boosting gene-silencing drug development

(Reuters) – Blackstone Group Inc said on Monday it invested $2 billion in Alnylam Pharmaceuticals Inc through an equity-and-debt deal, giving the drugmaker a financial boost to develop its gene-silencing therapies.

Alnylam, whose shares were nearly 7% higher in premarket trading, specializes in the development of medicines using the Nobel prize-winning RNA interference (RNAi) technology and earlier this month agreed to develop treatments for the new coronavirus with Vir Biotechnology Inc.

Blackstone said on Monday it purchased 50% of the royalties on global sales of Alnylam’s cholesterol therapy inclisiran, currently under review by the U.S. Food and Drug Administration. (reut.rs/3ckcTyF)

Inclisiran, belonging to a class of drugs that inhibit a protein known as PCSK9, was co-developed with The Medicines Co, which was bought by Novartis AG earlier this year.

The private equity firm said it would provide $1 billion in committed payments to Alnylam, a term loan of up to $750 million, and purchase $100 million of the drugmaker’s common stock.

Shares of Alnylam rose nearly 7% to $123.11 in premarket trading.

Alnylam was the first drugmaker to win U.S. approval for a treatment using the RNAi technology, which works by targeting and “silencing” specific genetic material, blocking the production of deadly proteins that cause diseases.

Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Aditya Soni

Source

Recent Articles

Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Receives ADLT Status for Envisia Genomic...

TFF Pharmaceuticals Comments on Animal Studies in the Development of High Potency Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals comments on animal studies in the development...

TTG Welcomes Bruce Anneaux to the Executive Team

HIGGINSVILLE, Mo.--(BUSINESS WIRE)-- #airadigmadventure--TTG has hired Dr. Bruce Anneaux as the...

Free, Automated Identification of Financial Aid for COVID-19 Treatment: Atlas Health Helps Hospitals, Uninsured & Underinsured Patients Mitigate “Surprise” Bills

SAN FRANCISCO--(BUSINESS WIRE)--Free, Automated Identification of Financial Aid for COVID Treatment:...

Zelis and Concert Genetics Launch Genetic Testing Claim Editing Solution

BEDMINSTER, N.J. & NASHVILLE, Tenn.--(BUSINESS WIRE)-- #HealthcareIndustry--Zelis, the healthcare industry’s leading...
2020 Call for Writers

Are you looking to inspire others in the pharma industry through your writing? You’re invited to submit your articles to become a Featured Writer for The Pharmaceutical Marketing Group website.